Identification and management of alcohol withdrawal syndrome
A Mirijello, C D'Angelo, A Ferrulli, G Vassallo… - Drugs, 2015 - Springer
Symptoms of alcohol withdrawal syndrome (AWS) may develop within 6–24 h after the
abrupt discontinuation or decrease of alcohol consumption. Symptoms can vary from …
abrupt discontinuation or decrease of alcohol consumption. Symptoms can vary from …
Gammahydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
MA Leone, F VignaTaglianti… - Cochrane database …, 2010 - cochranelibrary.com
Background Chronic excessive alcohol consumption may lead to dependence, and to
alcohol withdrawal syndrome (AWS) in case of abrupt drinking cessation. Gamma …
alcohol withdrawal syndrome (AWS) in case of abrupt drinking cessation. Gamma …
[HTML][HTML] Ethanol metabolism: The good, the bad, and the ugly
DF Wilson, FM Matschinsky - Medical hypotheses, 2020 - Elsevier
Throughout the world, ethanol is both an important commercial commodity and a source of
major medical and social problems. Ethanol readily passes through biological membranes …
major medical and social problems. Ethanol readily passes through biological membranes …
Ability of baclofen in reducing alcohol craving and intake: II—Preliminary clinical evidence
Background: Accumulating evidence shows the efficacy of the γaminobutyric acid (GABAB)
receptor agonist baclofen in reducing alcohol intake in rats, but no studies have been …
receptor agonist baclofen in reducing alcohol intake in rats, but no studies have been …
Ability of baclofen in reducing alcohol intake and withdrawal severity: I—Preclinical evidence
Background: The similarities between the pharmacological effects of the γaminobutyric acid
receptor agonist, baclofen, and the alcoholsubstituting agent, γhydroxybutyric acid, led us …
receptor agonist, baclofen, and the alcoholsubstituting agent, γhydroxybutyric acid, led us …
Management of alcohol dependence in patients with liver disease
G Addolorato, A Mirijello, L Leggio, A Ferrulli… - CNS drugs, 2013 - Springer
Alcohol dependence represents a chronic and relapsing disease affecting nearly 10% of the
general population both in the USA and in Europe, with a widespread burden of morbidity …
general population both in the USA and in Europe, with a widespread burden of morbidity …
Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol
The chronic use of alcohol can lead to the onset of an alcohol use disorder (AUD). About
50% of subjects with an AUD may develop alcohol withdrawal syndrome (AWS) when they …
50% of subjects with an AUD may develop alcohol withdrawal syndrome (AWS) when they …
Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity
The purpose of this review paper is to present evidence that rat animal models of alcoholism
provide an ideal platform for developing and screening medications that target alcohol …
provide an ideal platform for developing and screening medications that target alcohol …
Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence
GM Keating - Clinical Drug Investigation, 2014 - Springer
A liquid formulation of sodium oxybate (Alcover®), the sodium salt of γ-hydroxybutyric acid
(GHB), is approved in Italy and Austria for use in alcohol withdrawal syndrome and for the …
(GHB), is approved in Italy and Austria for use in alcohol withdrawal syndrome and for the …
Gammahydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine
G Addolorato, G Balducci, E Capristo… - Alcoholism: Clinical …, 1999 - Wiley Online Library
Background: Benzodiazepine has been shown to be one of the most effective class of drugs
in the management of alcohol withdrawal syndrome (AWS). Gammahydroxybutyric acid …
in the management of alcohol withdrawal syndrome (AWS). Gammahydroxybutyric acid …